Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax

6 Apr 2023

Abstract excerpt

Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclax Despite optimization and escalation of risk-based chemotherapy regimens, children with relapsed or chemotherapyrefractory acute leukemias, particularly acute myeloid leukemia (AML), remain difficult to cure.1,2 Traditional intensive cytotoxic chemotherapy salvage regimens require extended inpatient...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Lymphoblastic Leukemia research
Share to Acute Myeloid Leukemia Research
Share to Chronic Lymphocytic Leukemia Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37021525
DOI: 10.3324/haematol.2022.282637

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical responses in pediatric patients with relapsed/refractory leukemia treated with azacitidine and venetoclaxPMID 37021525Read ↗

Relapse and resistance in acute myeloid leukemia post venetoclax: improving second lines therapy and combinations.Semantic proximity Read ↗

Venetoclax combined with hypomethylating agents and the CAG regimen (DCAG) in relapsed/refractory AML: A single- center clinical trialSemantic proximity Read ↗

Successful remission induction therapy with azacitidine and venetoclax for a treatment-naive elderly patient with ETP/myeloid mixed-phenotype acute leukemia: a case reportSemantic proximity Read ↗

Efficacy and safety of venetoclax and azacitidine for acute myeloid leukemia in China: a real-world single-center studySemantic proximity Read ↗

Clinical Experience With Venetoclax in Patients With Newly Diagnosed, Relapsed, or Refractory Acute Myeloid Leukemia.Semantic proximity Read ↗

Addition of venetoclax to myeloablative conditioning regimens for allogeneic hematopoietic stem cell transplantation in high-risk AMLSemantic proximity Read ↗

[Efficacy of Venetoclax Plus Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia Patients with FLT3-ITD Mutation].Semantic proximity Read ↗

Efficacy of venetoclax and azacitidine based therapy in favorable-risk unfit acute myeloid leukemia: a real-world studySemantic proximity Read ↗

How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemiaSemantic proximity Read ↗

Post-stem cell transplant maintenance for pediatric acute leukemias: insights from a Brazilian institution with a Latin American perspectiveSemantic proximity Read ↗

Real-life Multicenter Experience of Long-term Treatment With Venetoclax Plus Azacitidine for Acute Myeloid Leukemia in ChinaSemantic proximity Read ↗

Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive ChemotherapySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.